Effect of HECNU in malignant supratentor
β
P. Georges; S. Przedborski; J. Brotchi; M. Chatel; D. GΓ©douin; J. Hildebrand
π
Article
π
1988
π
Springer US
π
English
β 453 KB
Forty adults with recurring brain gliomas were treated with HECNU 130 mg/m 2, given i.v. every 5 to 6 weeks (mean 5.4) and corticosteroids. According to the response to treatment, patients were divided in 3 groups: 1. Group I included 8 pts (20%) with objective remission, defined as a clear-cut clin